Respirerx Pharmaceuticals Inc. (RSPI) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

Respirerx Pharmaceuticals Inc.

CIK: 849636 Ticker: RSPI
Cover - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 31, 2022
Jun. 30, 2021
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Annual Reporttrue  
Document Transition Reportfalse  
Document Period End DateDec. 31, 2021  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2021  
Current Fiscal Year End Date--12-31  
Entity File Number1-16467  
Entity Registrant NameRespireRxPharmaceuticals Inc.  
Entity Central Index Key0000849636  
Entity Tax Identification Number33-0303583  
Entity Incorporation, State or Country CodeDE  
Entity Address, Address Line One126Valley Road  
Entity Address, Address Line TwoSuiteC  
Entity Address, City or TownGlenRock  
Entity Address, State or ProvinceNJ  
Entity Address, Postal Zip Code07452  
City Area Code(201)  
Local Phone Number444-4947  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
Entity Public Float  $ 2,476,607
Entity Common Stock, Shares Outstanding 97,894,276 
Documents Incorporated by ReferenceNONE  
ICFR Auditor Attestation Flagfalse  
Auditor Firm ID200  
Auditor LocationIrvine,California  

View differences made from one year to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..


Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Operations (Parenthetical)
Consolidated Statements Of Stockholders' Deficiency
Business (Details Narrative)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Commitments And Contingencies (Tables)
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Notes Payable
Notes Payable (Details Narrative)
Notes Payable (Tables)
Organization And Basis Of Presentation
Reconciliation Of Income Tax Rate Federal Statutory Rate And Effective Tax Rate (Details)
Related Party Transactions
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Schedule Of Convertible Notes Outstanding (Details)
Schedule Of Convertible Notes Payable (Details)
Schedule Of Deferred Tax Assets (Details)
Schedule Of Exercise Prices Of Common Stock Options Outstanding And Exercisable (Details)
Schedule Of Exercise Prices Of Common Stock Warrants Outstanding And Exercisable (Details)
Schedule Of Fair Value Of Warrants Estimated Using Black- Scholes Pricing Model With Valuation Assumptions (Details)
Schedule Of Warrants Activity (Details)
Settlement And Payment Agreements
Settlement And Payment Agreements (Details Narrative)
Stockholders??? Deficiency
Stockholders??? Deficiency (Details Narrative)
Stockholders??? Deficiency (Tables)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Current Cash Commitments In Employment Agreements (Details)
Summary Of Fair Value Of Option Estimated Using Black-Scholes Pricing Model With Valuation Assumptions (Details)
Summary Of Principal Cash Obligations And Commitments (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Stock Option Activity (Details)
Ticker: RSPI
CIK: 849636
Form Type: 10-K Annual Report
Accession Number: 0001493152-22-010053
Submitted to the SEC: Fri Apr 15 2022 2:12:30 PM EST
Accepted by the SEC: Fri Apr 15 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: